Trial Profile

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozanimod (Primary)
Indications Crohn's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Celgene Corporation; Celgene International SARL

Most Recent Events

11 Mar 2025 Status changed from completed to discontinued.
26 Nov 2024 Status changed from active, no longer recruiting to completed.
27 Aug 2024 Planned End Date changed from 24 Mar 2031 to 29 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com